摘要
目的观察莫沙必利治疗反流性食管炎的临床疗效及安全性。方法将90例患者随机分为观察组46例,对照组44例。观察组患者给予奥美拉唑20 mg/次,2次/d;莫沙必利5 mg/次,3次/d,口服。对照组患者给予奥美拉唑20 mg/次,2次/d;多潘立酮10 mg/次,3次/d,口服。两组均疗程4周,观察比较患者的临床疗效、内镜检查结果及不良反应。结果临床疗效比较,观察组为总有效率95.65%,对照组为79.55%,观察组优于对照组(P<0.05);内镜检查结果显示,观察组总有效率为89.13%,对照组为72.73%,观察组高于对照组(P<0.05)。两组均未出现严重不良反应。结论莫沙必利联合奥美拉唑治疗反流性食管炎疗效满意,症状缓解快,不良反应少,值得临床推广应用。
Objective To observe the curative effect and security of mosapride in reflux esophagitis. Methods Ninety patients with reflux esophagitis were divided randomly into two groups, experiment group and control group. All patients took omeprazole 20 mg twice a day,46 patients in experiment group took mosapride 5 mg three times a day,44 patients in control group took domperidone 10 mg three times a day in the same time. After 4 weeks, the therapeutic effect and endoscopic examination were compared between the two groups, adverse effects were recorded. Results The obvious effective rate of experiment group was higher than that of control group (95.65% VS 79.54% ,P 〈 0.05 ). The total effective rate of experiment group was higher than that of control group in endoscopic examination (89.13% VS 72.72%, P 〈 0.05 ). There was no obvious adverse effect in both groups. Conclusion Mosapride has satisfactory effect on treating reflux esophagitis and it can relieve clinical symptom of reflux esophagitis and have few adverse effects.
出处
《内科》
2012年第3期232-234,共3页
Internal Medicine